Supriya Lifescience eyes strong growth with speedy expansion

POSTED by NILESH WAGHELA

Mumbai: Supriya Lifescience Ltd, a prominent player in the active pharmaceutical ingredient (API) manufacturing sector is on fast expansion mode.

Company has exhibited a strong revenue growth on a YoY basis driven by robust growth in anaesthetic segment and double-digit growth in the vitamins segment.

The company was able to continue the growth momentum by penetrating into regulated markets such as Europe where the revenue contribution has significantly increased. Profitability margins expanded on account of favorable geographical mix and product mix, says, Director,  Supriya Lifescience Ltd, Ms. Saloni Wagh.

New product approvals, and scaling up of molecules in regulated markets will drive growth going forward, she added. 

The contract development manufacturing organisation projects which are in the pipeline can contribute significantly to top-line and profitability over the long term, said Satish Wagh, the Chairman and Managing Director (CMD) of Supriya Lifescience, sharing business updates and the way ahead for the business.

Supriya Lifescience, is a global leader in the production of Active Pharmaceutical Ingredients (APIs) and we are eyeing significant expansion in the Latin American market, he added further.

The company's successful registration of 10 APIs marks a key milestone, paving the way for an expected incremental revenue of ₹300 crore.

In an interaction with Business star, Mr. Satish Wagh,  highlighted that the achievement follows the certification of their manufacturing site in Maharashtra with good manufacturing practice approval from the Brazilian regulatory authority.

"We have already registered 10 APIs out of 15. I am hopeful that within the next two years, we will attain at least ₹300 crore more in the Latin American market, especially in Brazil," expressed Mr. Wagh.

Discussing the company's margin guidance, Mr. Wagh said, "We aim to double our margins within the next four years, and our EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) will continue to grow."